Aiforia vs Visiopharm (2026)
Both sell pathology AI certified under the EU IVDR and research use only in the United States, differing in how the AI reaches the laboratory. Aiforia's Clinical Suites cover five cancers on its own cloud platform, with Aiforia Create for building models. Visiopharm packages its algorithms as APPs for breast biomarkers and metastasis detection, lung PD-L1 and prostate cancer, validated to Agilent assays and sold with Agilent as the Visiopharm Diagnostic Package, running on the web, on premises or hybrid and integrating with Sectra and Proscia.
- You want a hosted cloud platform with its own worklist and viewer.
- You want to build your own models with Aiforia Create.
- Named certifications matter: ISO 27001, SOC 2 Type II and ISO 13485.
- You want on premises or hybrid deployment.
- Your laboratory runs Agilent assays and the Omnis platform.
- You want trial evidence from routine use: UMC Utrecht's CONFIDENT-B trial tested the metastasis APP in diagnosis.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Aiforia and Visiopharm are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Aiforia | Visiopharm |
|---|---|---|
| Primary category | Digital Pathology AI | Digital Pathology AI |
| Founded | 2013 | 2001 |
| Headquarters | Helsinki, Finland | Hoersholm, Denmark |
| Website | aiforia.com | visiopharm.com |
Side by Side
Select any grade to read the note behind it.
Each vendor in one paragraph
Written to be quoted whole. Each paragraph opens the AI Health Index profile of the vendor: what the product is, who buys it and what it does.
Finnish deep learning pathology company, listed in Helsinki, selling cloud based image analysis for clinical diagnostics and preclinical research. Its Aiforia Clinical Suites cover breast, lung, prostate, gastric and colon cancer on a platform with a worklist, viewer and case reporting; each clinical model is CE-IVD marked for diagnostic use in the EU and EEA under the IVDR, or research use only, and all are research use only in the United States.
Source: AI Health Index, September 2026
Danish pathology image analysis company whose diagnostic products are packaged as APPs, deep learning algorithms for specific tasks: HER2, Ki67, ER and PR scoring and metastasis detection in breast cancer, PD-L1 in non-small cell lung cancer, and prostate cancer. The CE-IVD APPs are certified under the EU IVDR for diagnostic use in the EU and UK and are not sold for diagnosis in the United States, where research APPs are offered; the company describes the PD-L1 APP as its ninth IVDR certification.
Source: AI Health Index, September 2026
Questions buyers ask
How do Aiforia and Visiopharm work with the EHR?
The clinical solutions page says Aiforia integrates into existing laboratory systems, with publicly available API specifications, and that customers choose among deployment options. A sales and marketing partnership with Siemens Healthineers extends distribution.
With Visiopharm, the integrations page names Sectra IDS7 and Proscia Concentriq AP, describes analysis triggered automatically from laboratory information system metadata, and states that the Sectra integration uses Sectra standards with no custom changes, shows overlays and results in the Sectra primary viewer, and can upload on-slide controls for internal quality testing. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 28, 2026. No vendor pays for placement.
How are Aiforia and Visiopharm priced and sold?
As a company publicly traded on the Helsinki exchange, Aiforia discloses revenue and financial performance under listing requirements, so its financial footing is public, but it discloses nothing on per case, per model or platform licensing cost.
The per APP packaging does imply a modular purchasing model, and availability through Agilent as the Visiopharm Diagnostic Package gives a second procurement route, but no rates, bundle structure, or per case economics are disclosed. Nothing says whether a license covers individual APPs or a portfolio, and because the clearances are narrow, coverage depends on exactly which algorithms are included. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 28, 2026. No vendor pays for placement.
Which settings and specialties do Aiforia and Visiopharm cover?
Aiforia Create serves preclinical and academic research separately. The site does not list the validated scanners and stains for each model.
In Visiopharm's case, the CE-IVD APPs cover breast (HER2, Ki67, ER, PR, metastasis detection), non-small cell lung cancer (PD-L1) and prostate, certified for diagnostic use in the EU and UK and not sold for diagnosis in the United States, where research APPs are offered. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 28, 2026. No vendor pays for placement.
What evidence is published for Aiforia and Visiopharm?
Academic work using the Aiforia Create platform appears in Nature and in Mayo Clinic and MSKCC studies, though most of that is research use rather than validation of the clinical suites.
With Visiopharm, the company links the paper and reports the same site's positive business case. For the PD-L1 APP it describes a study across three European sites against a multi reader reference, and metastasis detection verification on breast and colorectal data from three sites. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 28, 2026. No vendor pays for placement.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Digital Pathology AI page.
Neither is FDA cleared. Neither publishes pricing. Rewritten 28 Sep 2026 after both records were reviewed.